![Figure 1. NOS inhibition and hepatic venous thrombosis. Masson trichrome stains of representative livers from WT+L-NAME (A-C), WT+L-NAME+tiplaxtinin (PAI-039) (D-F), and PAI-1-/-+L-NAME (G-I) mice after 6 weeks of L-NAME treatment at the indicated magnifications. Arrows illustrate the extent of venous thrombi in WT mice. Images were visualized using an Olympus BX40 microscope equipped with 10×/0.30, 20×/0.50, and 40×/0.90 Plan Apo objective lenses and an Optronics digital camera (Optronics, Goleta, CA). Images were acquired with Magnafire 1.0 software (Optronics) and were processed for publication with Image Pro Plus 4.5 software (Media Cybernetics, Silver Spring, MD). (J) Calculated percent occluded luminal area in all 3 treatment groups (P < .001 for WT vs PAI-1 knockout [KO]; and P < .001 for WT vs WT+tiplaxtinin by ANOVA). Values shown are mean ± SEM.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/107/1/10.1182_blood-2005-07-2681/4/zh80010689050001.jpeg?Expires=1743174651&Signature=qyYPJDEsCKgkWsPXp~BSKs2mkJHIAM~JnxeOwrIRA1jrYuRYfvNBN7gFvh6VDcsbJ~wznVCFyP01BEM6ReCY8oOPmFly9tc16tPpykXX9X~63uye9nKYTWRyBiObtopGp0-1blr7k1F~preIguvLCnyhh2eGD~YsIhPyZnZ8mbw580Rv1pdwpEE3~UUK5VcqgS8cW6co7GkdCOPogr~F-88VnpXFZZGbYZUfvZqA~d2GaXjX4iOo1EQNz29kMLINjJkuyA5UoWxNG4HyluXaq4IDHUCAarKdD1~cYkQNKM6rBhga3sNxZyv8SM1bPqheB~pj5kldmcO3Ov5bJO~x~Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
NOS inhibition and hepatic venous thrombosis. Masson trichrome stains of representative livers from WT+L-NAME (A-C), WT+L-NAME+tiplaxtinin (PAI-039) (D-F), and PAI-1-/-+L-NAME (G-I) mice after 6 weeks of L-NAME treatment at the indicated magnifications. Arrows illustrate the extent of venous thrombi in WT mice. Images were visualized using an Olympus BX40 microscope equipped with 10×/0.30, 20×/0.50, and 40×/0.90 Plan Apo objective lenses and an Optronics digital camera (Optronics, Goleta, CA). Images were acquired with Magnafire 1.0 software (Optronics) and were processed for publication with Image Pro Plus 4.5 software (Media Cybernetics, Silver Spring, MD). (J) Calculated percent occluded luminal area in all 3 treatment groups (P < .001 for WT vs PAI-1 knockout [KO]; and P < .001 for WT vs WT+tiplaxtinin by ANOVA). Values shown are mean ± SEM.
